KITE - Kite Pharma, Inc.

. Currency in USD
-
-
Stock chart is not supported by your current browser
Previous CloseN/A
OpenN/A
BidN/A x N/A
AskN/A x N/A
Day's RangeN/A - N/A
52 Week Rangeundefined - undefined
VolumeN/A
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Gilead shares up after FDA approves breakthrough cancer treatment
    Yahoo Finance Video11 months ago

    Gilead shares up after FDA approves breakthrough cancer treatment

    The FDA has approved a new cancer treatment developed by Gilead's $11B acquisition Kite Pharma. Yahoo Finance’s Alexis Christoforous, Rick Newman, and Nicole Sinclair have more.

  • InvestorPlace8 months ago

    No Reason To Rush Into Juno Therapeutics Inc Stock After This Big Pop

    Juno Therapeutics Inc (NASDAQ:JUNO) stock is up about 50% after the Wall Street Journal reported on Tuesday that biotech giant Celgene Corporation (NASDAQ:CELG) is in talks to buy the company. Juno Therapeutics is a pioneer in the booming cell therapy industry, where biotech companies are developing modified human immune cells to combat cancer cells.

  • GuruFocus.com9 months ago

    5 Companies Reach 52-Week Highs

    A number of companies have achieved annual milestones

  • Why Gilead Sciences Stock Should Be Avoided in 2018
    Motley Fool9 months ago

    Why Gilead Sciences Stock Should Be Avoided in 2018

    Gilead's foray into the adoptive cell-therapy space doesn't bode well for its prospects next year.

  • Don't Count on Gilead Buying Galapagos
    Bloomberg9 months ago

    Don't Count on Gilead Buying Galapagos

    The drugmaker needs a deal, but this European biotech isn't it.

  • Gilead Sciences to Acquire Cell Design Labs for $567 Million
    Zacks9 months ago

    Gilead Sciences to Acquire Cell Design Labs for $567 Million

    Gilead Sciences, (GILD) and its subsidiary Kite announced that they have inked an agreement to acquire Cell Design Labs, for an upfront payment of $175 million.

  • Does Gilead's Kite Acquisition Offer A New Buying Opportunity?
    Investor's Business Daily10 months ago

    Does Gilead's Kite Acquisition Offer A New Buying Opportunity?

    Gilead caught an upgrade following its Kite buyout and the promise shown with new cancer drugs.

  • Benzinga10 months ago

    Maxim Explains Why Gilead Sciences Is A Now A Buy

    Gilead Sciences, Inc. (NASDAQ: GILD ) stands to benefit on multiple fronts, which prompted an analyst to upgrade the shares of the company Thursday. The Analyst Maxim Group analyst Jason McCarthy upgraded ...

  • Gilead Sciences Stock Upgraded: This Is the Power of Free
    Motley Fool10 months ago

    Gilead Sciences Stock Upgraded: This Is the Power of Free

    Wall Street cannot resist buying a stock on sale -- and for better or worse, Gilead often seems to be on sale.

  • 7 Life Science Stocks to Buy Today
    InvestorPlace10 months ago

    7 Life Science Stocks to Buy Today

    Biotech and life sciences stocks have had a great run-up so far in 2017. Through the end of October, the S&P Biotechnology Select Sector Industry Index (SPSIBI) is up 52%. That makes the life science stocks some of best performers around. And what’s not to like?

  • American City Business Journals11 months ago

    Juno touts latest cancer drug results after rivals win FDA approval

    Juno Therapeutics Inc. has announced new cancer trial results that could help the drugmaker leapfrog key competitors in the rapidly emerging cancer immunotherapy industry. Juno said the latest data from its lead product candidate, called JCAR017, are stronger than from Novartis Pharmaceuticals Corp. and Kite Pharma Inc. Both rivals recently won Food and Drug Administration approval to start selling their CAR-T (chimeric antigen receptor T cell) treatments. "There's been this odd belief that all CAR-Ts are the same," Juno President of Research and Development Dr. Sunil Agarwal said Wednesday.

  • 3 Healthcare Value Stocks
    Motley Fool11 months ago

    3 Healthcare Value Stocks

    It might be hard to find value-priced healthcare stocks, but Gilead Sciences, Masimo, and AbbVie qualify if investors know how to look at them.

  • Market Realist11 months ago

    Gilead Sciences on the Street: Analyst Recommendations in October

    Of the 28 analysts tracking Gilead Sciences in October 2017, three have recommended a “strong buy,” while 11 have recommended a “buy."

  • 6 Top Biotech Companies In Innovation Earn Recognition In New Awards
    Investor's Business Daily11 months ago

    6 Top Biotech Companies In Innovation Earn Recognition In New Awards

    Cancer. Alzheimer’s. MS. Treatments from the fast-growing U.S. biotech industry provide new hope for patients. What are the top biotech companies in innovation?

  • Kite Pharma Cancer Treatment Stands Out In Hot CAR-T Field
    Investor's Business Daily11 months ago

    Kite Pharma Cancer Treatment Stands Out In Hot CAR-T Field

    Gilead's new Kite Pharma unit is a leader in cutting-edge CAR-T therapy that fights cancer by rebuilding a patient's cells. Here's how its treatment stands out and who it helps.

  • It’s Time to Start Buying Beaten-Up Gilead Sciences, Inc. (GILD) Stock
    InvestorPlace11 months ago

    It’s Time to Start Buying Beaten-Up Gilead Sciences, Inc. (GILD) Stock

    Then there was the demise of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), followed by an EpiPen scandal at Mylan N.V. (NASDAQ:MYL). While GILD stock also fell, the reasons were largely unrelated to the scandals which plagued its peers. The company’s big Hepatitis C Virus (HCV) drug worked really well.

  • Going Long Pfizer Inc. (PFE) Stock Is an Easy Pill to Swallow
    InvestorPlace11 months ago

    Going Long Pfizer Inc. (PFE) Stock Is an Easy Pill to Swallow

    Pfizer Inc. (NYSE:PFE) has had a decent year, rising 11% year-to-date and 8% in the past 12 months. Fundamentally, PFE stock could play catch up since its value is mid-range compared to its competitors. Today’s trade is bullish PFE stock.

  • Here's Why Juno Therapeutics Stock May Still Be Worth Buying
    Motley Fool11 months ago

    Here's Why Juno Therapeutics Stock May Still Be Worth Buying

    Juno Therapeutics stock has been on the move as investors speculate on the next CAR-T buyout target. But there are other compelling reasons to own this stock right now.

  • The 5 Best M&A Deals of 2017 (So Far!)
    Zackslast year

    The 5 Best M&A Deals of 2017 (So Far!)

    Over the past few years, consolidation has become an important trend in nearly every major global industry. To celebrate this, we've compiled our list of the most important M&As of 2017!

  • Business Wirelast year

    Gilead Sciences Completes Acquisition of Kite Pharma, Inc.

    Gilead Sciences, Inc. today announced the completion of the previously announced transaction for Dodgers Merger Sub, Inc., a wholly-owned subsidiary of Gilead , to acquire Kite Pharma, Inc.